Phthalazine-containing antidiabetic compounds

1. A compound of formula

or a pharmaceutically acceptable salt thereof,

wherein:

G is a N—N containing heteroaryl group G selected from the group consisting of

which is optionally substituted by at least one R 2 ;

L is —O—, —C(O)—, —S(O) q —, —N(R 3 )—;

X is —O—, —C(O)—, —S(O) q , —C(R a )(R b )— or —N(R 8 )-;

Y is —[C(R a )(R b )] n —O—[C(R a )(R b )] n , —[C(R a )(R b )] n -C(O)-[C(R a )(R b )] n , —[C(R a )(R b )] n -S(O) q -[C(R a )(R b )] n —, —[C(R a )(R b )] m — or —N(R 8 )-,

provided that when X is —O—, Y cannot be —O—[C(R a )(R b )] n —;

R is a group selected from the group consisting of

(i)

(ii)

(iii)

(iv)

(v)

tetrazolyl; and

(vii)

wherein

Q is —CH— or —N—, and

J is —S—, —CH 2 -, —O— or N(R 8 )-;

R a is independently selected from the group consisting of H, —OH, halo, alkoxy, cycloalkyl, and cycloalkylalkyl;

R b is independently selected from the group consisting of H, —OH, halo, alkoxy, cycloalkyl, and cycloalkylalkyl;

R 1 is independently selected from the group consisting of H, halogen, —SF 5 , —CN, —NO 2 , —N(R 6 )(R 7 ), —OH, alkyl, alkoxy, cycloalkyl, cycloalkyloxy, cycloalkylalkyl, cycloalkylalkoxy, and —S(O) q -alkyl, wherein said alkyl, alkoxy, cycloalkyl, cycloalkyloxy, cycloalkylalkyl, and cycloalkylalkoxy are optionally substituted with one or more groups selected from the group consisting of —OH, halo, alkyl, —S(O) q -alkyl, haloalkyl, alkoxy, haloalkoxy, and cycloalkyl;

R 2 is independently selected from the group consisting of halogen, —CN, —NO 2 , —N(R 6 )(R 7 ), OH, alkyl, alkoxy, cycloalkyl, cycloalkyloxy, cycloalkylalkyl, cycloalkylalkoxy, aryl, arylalkyl, heteroaryl, heteroarylalkyl and —S(O) q -alkyl, wherein said alkyl, alkoxy, cycloalkyl, cycloalkyloxy, cycloalkylalkyl, cycloalkylalkoxy, aryl, arylalkyl, heteroaryl, and heteroarylalkyl are optionally substituted with one or more groups selected from the group consisting of —OH, halo, alkyl, —S(O) q -alkyl, haloalkyl, alkoxy, haloalkoxy, and cycloalkyl;

R 3 is independently selected from the group consisting of H, alkyl and haloalkyl;

R 4 is independently selected from the group consisting of H, alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, and heteroarylalkyl;

R 5 is independently selected from the group consisting of H, alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, and heteroarylalkyl;

R 6 is independently selected from the group consisting of H, alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl and heteroarylalkyl;

R 7 is independently selected from the group consisting of H, alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, and heteroarylalkyl;

or R 6 and R 7 together form a 4- to 7-membered heterocycloalkyl or a 5-membered heteroaryl ring optionally having, in addition to the N atom, 1 or 2 heteroatoms selected from the group consisting of O, N(R 8 ), N or S, wherein said rings are optionally substituted by one or more R 12 moieties;

R 8 is independently selected from the group consisting of H, alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, heteroarylalkyl, —C(O)—R 5 , —C(O)O—R 5 , —C(O)N(R 6 )(R 7 ), —C(O)-alkylene-OR 4 , —C(O)-alkylene-N(R 6 )(R 7 ), —C(O)-alkylene-S(O) q -R 5 , —S(O) q -R 5 , —S(O) q -alkylene-OR 4 , —S(O) q -alkylene-N(R 6 )(R 7 ), -alkylene-OR 4 , -alkylene-S(O) q -R 5 , -alkylene-N(R 6 )(R 7 ), and —S(O) 2 N(R 6 )(R 7 ) wherein said alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, heteroarylalkyl and alkylene are optionally substituted with one or more groups selected from the group consisting of —OH, halo, alkyl, haloalkyl, alkoxy, haloalkoxy and cycloalkyl;

R 9 is independently selected from the group consisting of H, alkyl, haloalkyl;

R 10 is independently selected from the group consisting of H, —OH, alkyl, alkyl, cycloalkyl or alkoxy wherein said alkyl, alkyl, cycloalkyl or alkoxy groups are optionally substituted with at least one substituents selected from the group consisting of halo and —OR 5;

R 11 is independently selected from the group consisting of H, alkyl, and haloalkyl;

wherein each of the alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, and heteroarylalkyl groups in R 4 , R 5 , R 6 and R 7 are independently unsubstituted or substituted by one or more R 12 groups, where

R 12 is independently selected from the group consisting of alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, heteroarylalkyl, —OR 4 , —C(O)—R 5 , C(O)O—R 5 , —S(O) q -R 5 , —N(R 5 )(R 6 ), —C(O)N(R 6 )(R 7 ), and —S(O) 2 N(R 6 )(R 7 ), —NO 2 , —SF 5 , —CN, and halo and wherein each alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, and heteroarylalkyl group in R 12 is independently unsubstituted or substituted by one or more R 13 groups where

R 13 is independently selected from the group consisting of alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, heteroarylalkyl, —OR 4 , —C(O)—R 5 , —C(O)O—R 5 , —S(O) q -R 5 , —C(O)N(R 6 )(R 7 ), and —S(O) 2 N(R 6 )(R 7 ), —NO 2 , —SF 5 , —CN, and halo;

m is independently 1, 2, or 3;

n is independently 0, 1 or 2;

p is 0, 1, 2, or 3;

q is independently 0, 1, or 2;

heteroaryl is independently selected from the group consisting of pyridyl, pyrazinyl, furanyl, thienyl, pyrimidinyl, isoxazolyl, isothiazolyl, oxazolyl, thiazolyl, pyrazolyl, furazanyl, pyrrolyl, pyrazolyl, triazolyl, 1,2,4-thiadiazolyl, pyrazinyl, pyridazinyl, quinoxalinyl, phthalazinyl, imidazo[1,2-a]pyridinyl, imidazo[2,1-b]thiazolyl, benzofurazanyl, indolyl, azaindolyl, benzimidazolyl, benzothienyl, quinolinyl, imidazolyl, thienopyridyl, quinazolinyl, thienopyrimidyl, pyrrolopyridyl, imidazopyridyl, isoquinolinyl, benzoazaindolyl, 1,2,4-triazinyl and benzothiazolyl; and

heterocycloalkyl or heterocyclyl is independently selected from piperidyl, piperazinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, 1,4-dioxanyl, tetrahydrofuranyl, tetrahydrothiophenyl, imidazolidinyl and pyrazolidinyl.

2. The compound according to claim 1 of the formula

or a pharmaceutically acceptable salt thereof wherein

G is a N—N containing heteroaryl group selected from the group consisting of

which is optionally substituted by at least one R 2 ;

L is —O—, —C(O)—, —S(O) q -, or —N(R 3 )-;

R is a group selected from the group consisting of

(i)

(ii)

(iii)

(iv)

(v)

(vi) tetrazolyl; and

(vii)

wherein

Q is —CH— or —N—, and

J is —S—, —CH 2 -, —O— or N(R 8 )-;

R 1 is independently selected from the group consisting of H, halogen, —SF 5 , —S(O) q -alkyl, —CN, —NO 2 , —N(R 6 )(R 7 ), —OH, alkyl, alkoxy, cycloalkyl, cycloalkyloxy, cycloalkylalkyl, and cycloalkylalkoxy wherein said alkyl, alkoxy, cycloalkyl, cycloalkyloxy, cycloalkylalkyl, and cycloalkylalkoxy are optionally substituted with one or more groups selected from the group consisting of —OH, halo, —S(O) q -alkyl, alkyl, haloalkyl, alkoxy, haloalkoxy, and cycloalkyl;

R 2 is independently selected from the group consisting of halogen, alkyl, haloalkyl, cyano, amino, alkylamino and dialkylamino;

R 3 is independently selected from the group consisting of H, alkyl, haloalkyl;

R 4 is independently selected from the group consisting of H, alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, and heteroarylalkyl;

R 5 is independently selected from the group consisting of H, alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, and heteroarylalkyl;

R 6 is independently selected from the group consisting of H, alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl and heteroarylalkyl;

R 7 is independently selected from the group consisting of H, alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, and heteroarylalkyl;

or R 6 and R 7 together form a 4- to 7-membered heterocycloalkyl or a 5-membered heteroaryl ring optionally having, in addition to the N atom, 1 or 2 heteroatoms selected from the group consisting of O, N(R 8 ), N or S, wherein said rings are optionally substituted by one or more R 12 moieties;

R 8 is independently selected from the group consisting of

H, alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, heteroarylalkyl, —C(O)—R 5 , —C(O)O—R 5 , —C(O)N(R 6 )(R 7 ), —C(O)-alkylene-OR 4 , —C(O)-alkylene-N(R 6 )(R 7 ), —C(O)-alkylene-S(O) q -R 5 , —S(O) q -R 5 , —S(O) q -alkylene-OR 4 , —S(O) q -alkylene-N(R 6 )(R 7 ), -alkylene-OR 4 , -alkylene-S(O) q -R 5 , -alkylene-N(R 6 )(R 7 ), and —S(O) 2 N(R 6 )(R 7 ) wherein said alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, heteroarylalkyl and alkylene are optionally substituted with one or more groups selected from the group consisting of —OH, halo, alkyl, haloalkyl, alkoxy, haloalkoxy and cycloalkyl;

R 9 is independently selected from the group consisting of H, alkyl, haloalkyl;

R 10 is independently selected from the group consisting of H, —OH, alkyl, alkyl, cycloalkyl or alkoxy wherein said alkyl, alkyl, cycloalkyl or alkoxy groups are optionally substituted with at least one substituent selected from the group consisting of halo and —OR 5 ;

R 11 is independently selected from the group consisting of H, alkyl, and haloalkyl;

wherein each of the alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, and heteroarylalkyl groups in R 4 , R 5 , R 6 , and R 7 are independently unsubstituted or substituted by one or more R 12 groups, wherhe

R 12 is independently selected from the group consisting of alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, heteroarylalkyl, —OR 4 , —C(O)—R 5 , —C(O)O—R 5 , —S(O) q -R 5 , —C(O)N(R 6 )(R 7 ), and —S(O) 2 N(R 6 )(R 7 ), —NO 2 , —SF 5 , —CN, —N(R 6 )(R 7 ) and halo and wherein each alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, and heteroarylalkyl group in R 12 is independently unsubstituted or substituted by one or more R 13 groups, where

R 13 is independently selected from the group consisting of alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, heteroarylalkyl, —OR 4 , —C(O)—R 5 , —C(O)O—R 5 , —S(O) q -R 5 , —C(O)N(R 6 )(R 7 ), and —S(O) 2 N(R 6 )(R 7 ), NO 2 , —SF 5 , —CN, and halo;

p is 0, 1, 2, or 3;

q is independently 0, 1, or 2;

heteroaryl is independently selected from the group consisting of pyridyl, pyrazinyl, furanyl, thienyl, pyrimidinyl, isoxazolyl, isothiazolyl, oxazolyl, thiazolyl, pyrazolyl, furazanyl, pyrrolyl, pyrazolyl, triazolyl, 1,2,4-thiadiazolyl, pyrazinyl, pyridazinyl, quinoxalinyl, phthalazinyl, imidazo[1,2-a]pyridinyl, imidazo[2,1-b]thiazolyl, benzofurazanyl, indolyl, azaindolyl, benzimidazol, benzothienyl, quinolinyl, imidazolyl, thienopyridyl, quinazolinyl, thienopyrimidyl, pyrrolopyridyl, imidazopyridyl, isoquinolinyl, benzoazaindolyl, 1,2,4-triazinyl and benzothiazolyl; and

heterocycloalkyl or heterocyclyl is independently selected from piperidyl, pyrrolidinyl, piperazinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, 1,4-dioxanyl, tetrahydrofuranyl, tetrahydrothiophenyl, imidazolidinyl and pyrazolidinyl.

3. The compound according to claim 1 of the formula

or a pharmaceutically acceptable salt thereof wherein

G is a N—N containing heteroaryl group selected from the group consisting of

which is optionally substituted by at least one R 2 ;

L is —O—, —C(O)—, —S(O) q -, or —N(R 3 )-;

R is a group selected from the group consisting of

(i)

(ii)

(iii)

(iv)

(v)

(vi) tetrazolyl; and

(vii)

wherein

Q is —CH— or —NR—, and

J is —S—, —CH 2 —; —O— or —N(R 8 )-;

R 1 is independently selected from the group consisting of H, halogen, —SF 5 , —S(O) q -alkyl, —CN, —NO 2 , —N(R 6 )(R 7 ), —OH, alkyl, alkoxy, cycloalkyl, cycloalkyloxy, cycloalkylalkyl, and cycloalkylalkoxy wherein said alkyl, alkoxy, cycloalkyl, cycloalkyloxy, cycloalkylalkyl, and cycloalkylalkoxy are optionally substituted with one or more groups selected from the group consisting of —OH, halo, —S(O) q -alkyl, alkyl, haloalkyl, alkoxy, haloalkoxy, and cycloalkyl;

R 2 is independently selected from the group consisting of halogen, alkyl, haloalkyl, cyano, amino, alkylamino and dialkylamino;

R 3 independently selected from the group consisting of H, alkyl, haloalkyl;

R 4 is independently selected from the group consisting of H, alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, and heteroarylalkyl;

R 5 is independently selected from the group consisting of H, alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, and heteroarylalkyl;

R 6 is independently selected from the group consisting of H, alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl and heteroarylalkyl;

R 7 is independently selected from the group consisting of H, alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, and heteroarylalkyl;

or R 6 and R 7 together form a 4- to 7-membered heterocycloalkyl or a 5-membered heteroaryl ring optionally haying, in addition to the N atom, 1 or 2 heteroatoms selected from the group consisting of O, N(R 8 ), N or S, wherein said rings are optionally substituted by one or more R 12 moieties;

R 8 is independently selected from the group consisting of H, alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, heteroarylalkyl, —C(O)—R 5 , —C(O)O—R 5 , —C(O)N(R 6 )(R 7 ), —C(O)-alkylene-OR 4 , —C(O)-alkylene-N(R 6 )(R 7 ), —C(O)-alkylene-S(O) q -R 5 , —S(O) q -R 5 , —S(O) q -alkylene-OR 4 , —S(O) q -alkylene-N(R 6 )(R 7 ), -alkylene-OR 4 , -alkylene-S(O) q -R 5 , -alkylene-N(R 6 )(R 7 ), and —S(O) 2 N(R 6 )(R 7 ) wherein said alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, heteroarylalkyl and alkylene are optionally substituted with one or more groups selected from the group consisting of —OH, halo, alkyl, haloalkyl, alkoxy, haloalkoxy and cycloalkyl;

R 9 is independently selected from the group consisting of H, alkyl, haloalkyl;

R 10 is independently selected from the group consisting of H, —OH, alkyl, alkyl, cycloalkyl or alkoxy wherein said alkyl, alkyl, cycloalkyl or alkoxy groups are optionally substituted with at least one substituent selected from the group consisting of halo and —OR 5;

R 11 is independently selected from the group consisting of H, alkyl, and haloalkyl;

wherein each of the alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, and heteroarylalkyl groups in R 4 , R 5 , R 6 , and R 7 are independently unsubstituted or substituted by one or more R 12 groups, where

R 12 is independently selected from the group consisting of alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, heteroarylalkyl, —OR 4 , —C(O)—R 5 , C(O)O—R 5 , —S(O) q -R 5 , —C(O)N(R 6 )(R 7 ), and —S(O) 2 N(R 6 )(R 7 ), —NO 2 , —SF 5 , —CN, —N(R 6 )(R 7 ) and halo and wherein each alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, and heteroarylalkyl group in R 12 is independently unsubstituted or substituted by one or more R 13 groups, where

R 13 is independently selected from the group consisting of alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, heteroarylalkyl, —OR 4 -C(O)—R 5 , C(O)O—R 5 , —S(O) q -R 5 , —C(O)N(R 6 )(R 7 ), and —S(O) 2 N(R 6 )(R 7 ), —NO 2 , —SF 5 , —CN, and halo;

p is 0, 1, 2, or 3;

q is independently 0, 1, or 2;

heteroaryl is independently selected from the group consisting of pyridyl, pyrazinyl, furanyl, thienyl, pyrimidinyl, isoxazolyl, isothiazolyl, oxazolyl, thiazolyl, pyrazolyl, furazanyl, pyrrolyl, pyrazolyl, triazolyl, 1,2,4-thiadiazolyl, pyrazinyl, pyridazinyl, quinoxalinyl, phthalazinyl, imidazo[1,2-a]pyridinyl, imidazo[2,1-b]thiazolyl, benzofurazanyl, indolyl, azaindolyl, benzimidazolyl, benzothienyl, quinolinyl, imidazoiyl, thienopyridyl, quinazolinyl, thienopyrimidyl, pyrrolopyridyl, imidazopyridyl, isoquinolinyl, benzoazaindolyl, 1,2,4-triazinyl and benzothiazolyl; and

heterocycloalkyl or heterocyclyl is independently selected from piperidyl, pyrrolidinyl, piperazinyl, morpholinyl, thiazolidinyl, 1,4-dioxanyl, tetrahydrofuranyl, tetrahydrothiophenyl, imidazolidinyl and pyrazolidinyl.

4. The compound according to claim 1 which is selected from the group consisting of

or a pharmaceutically acceptable salt thereof.

5. The compound according to claim 1 wherein G is

6. The compound according to claim 2 wherein G is

7. The compound according to claim 3 wherein G is

8. The compound according to claim 1 wherein R is

wherein

Q is —CH—;

J is —S—, and

R 8 is H or —(C 1 -C 4 )alkyl.

9. The compound according to claim 2 wherein R is

wherein

Q is —CH—,

J is —S—, and

R 8 is H or —(C 1 -C 4 )alkyl.

10. The compound according to claim 3 wherein R is

wherein

Q is —CH—, and

J is —S—, and

R 8 is H or —(C 1 -C 4 )alkyl.

11. A pharmaceutical composition comprising a pharmaceutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

12. A method for controlling insulin levels in a mammal in need thereof which comprises administering an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof to said mammal.

13. A method for treatment of Type-2 diabetes mellitus in a mammal in need thereof which comprises administering an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof to said mammal.

14. A method for the treatment of conditions related to Type-2 diabetes in a mammal in need thereof which comprises administering an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof to said mammal.

15. The method according to claim 14 wherein the condition is insulin resistance, obesity or lipid disorders.

16. The method for the treatment of Syndrome X in a mammal in need thereof which comprises administering an effective amount of a compound of according to claim 1 or a pharmaceutically acceptable salt thereof to said mammal.